Search This Blog

Friday, October 26, 2018

Regenxbio Treatment of CLN2 disease granted orphan designation


Regenxbio’s treatment of neuronal ceroid lipofuscinosis type 2, or CLN2, disease was granted orphan designation by the FDA, according to a post to the agency’s website.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)